Development of a CHO cell line for stable production of recombinant antibodies against human MMP9

Jina Ryu, Eun Jung Kim, Joo Kyung Kim, Tai Hyun Park, Byung Gee Kim, Hee Jin Jeong

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Background: Human matrix metalloproteinase 9 (hMMP9) is a biomarker in several diseases, including cancer, and the need for developing detectors and inhibitors of hMMP9 is increasing. As an antibody against hMMP9 can be selectively bound to hMMP9, the use of anti-MMP9 antibody presents new possibilities to address hMMP9-related diseases. In this study, we aimed to establish a stable Chinese hamster ovary (CHO) cell line for the stable production of antibodies against hMMP9. Results: Weconstructed recombinant anti-hMMP9 antibody fragment-expressing genes and transfected these to CHO cells. We chose a single clone, and successfully produced a full-sized antibody against hMMP9 with high purity, sensitivity, and reproducibility. Subsequently, we confirmed the antigen-binding efficiency of the antibody. Conclusions: We developed a novel recombinant anti-hMMP9 antibody via a CHO cell-based mammalian expression system, which has a high potential to be used in a broad range of medical and industrial areas.

Original languageEnglish
Article number8
JournalBMC Biotechnology
Issue number1
StatePublished - Dec 2022

Bibliographical note

Publisher Copyright:
© 2022, The Author(s).


  • CHO cell line
  • Matrix metalloproteinase 9
  • Recombinant antibody


Dive into the research topics of 'Development of a CHO cell line for stable production of recombinant antibodies against human MMP9'. Together they form a unique fingerprint.

Cite this